BioSyent Releases Financial Results for Third Quarter and First Nine Months of 2020

By Dr. Matthew Watson

MISSISSAUGA, Ontario, Nov. 26, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and nine months ended September 30, 2020. Key highlights include:

See original here:
BioSyent Releases Financial Results for Third Quarter and First Nine Months of 2020

Arbutus Announces 2021 Corporate Objectives and Provides Financial Update - January 25th, 2021
Abeona Therapeutics Announces Successful Type B Meeting with FDA for Pivotal Phase 3 VIITAL™ Study of EB-101 in Recessive Dystrophic Epidermolysis... - January 25th, 2021
Saniona received approximately USD $2.9 million (SEK 24.2 million) upfront payment in connection with Cadent Therapeutics transaction - January 25th, 2021
aTyr Pharma Presents Findings Further Validating NRP2 as a Potential Regulator of Solid Tumor Progression - January 25th, 2021
Cidara Therapeutics Announces Key Additions to its Board of Directors - January 25th, 2021
BrightInsight Names Technology and Healthcare Leaders to Advisory Council - January 25th, 2021
Albireo Announces U.S. FDA Acceptance of New Drug Application for Odevixibat - January 25th, 2021
Better Choice Company Appoints Jenny Condon as Executive Vice President of Digital Sales - January 25th, 2021
Vericel Announces Appointment of Joe Mara as Chief Financial Officer - January 25th, 2021
Caladrius Biosciences Announces Participation in Upcoming Virtual Conferences in February 2021 - January 25th, 2021
Golden Leaf Receives Approval to Extend Maturity of Convertible Debentures - January 25th, 2021
Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide... - January 25th, 2021
Medexus Announces Renewal and Expansion of Canadian Distribution Agreement for NYDA® - January 25th, 2021
Todos Medical Announces Strategic Investment by Yozma Group Korea - January 25th, 2021
Neuropathix, Inc. CEO Recaps 2020 Advances and Potential Ahead - January 25th, 2021
Information regarding the results of mandatory redemption of shares - January 25th, 2021
Tauriga Sciences Inc. Completes the Package Design for Its Cherry Lime Rickey Flavor, Caffeine Infused Tauri-Gum Version - January 25th, 2021
Eurobio Scientific: EXCEPTIONAL 2020 TURNOVER OF € 189 MILLION (+ 220%) - January 25th, 2021
Valneva and Instituto Butantan Sign Final Agreement on Single-Shot Chikungunya Vaccine for Low and Middle Income Countries - January 25th, 2021
GENFIT: Sweeping approval of OCEANEs buyback and amendments of terms - January 25th, 2021
Codiak’s Versatile engEx™ Platform for Engineered Exosomes Published in the Journal Molecular Therapy - January 23rd, 2021
CorMedix Inc. to Begin Trading on the Nasdaq Stock Exchange - January 23rd, 2021
Auxly Announces Upsized Bought-Deal Public Offering to $17.5 Million - January 23rd, 2021
Trishula Therapeutics Appoints Anil Singhal as Chief Executive Officer - January 23rd, 2021
MDxHealth Launches Capital Increase and Provides Preliminary 2020 Financial Results - January 23rd, 2021
DEINOVE strengthens its Business development team to deploy its partnering strategy - January 23rd, 2021
Hollister Biosciences Inc. Announces an Increase in Private Placement to $6.5 Million - January 23rd, 2021
Novavax Names Madelyn Caltabiano Senior Vice President, Global Program Management - January 23rd, 2021
Zealand Pharma announces update to 2020 financial guidance - January 23rd, 2021
Blood Sugar Premier – Does This Supplement Really Works? Ingredients & Blood Sugar Premier Reviews by Nuvectramedical - January 23rd, 2021
Bespoke Extracts Announces $100K Investment From CEO and Addition of New Brand Ambassador, UFC Fighter Maryna Moroz - January 22nd, 2021
Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for Primary Prevention of Cardiovascular Diseases - January 22nd, 2021
MDxHealth Successfully Completes a EUR 25.0 Million (USD 30.4 Million)(1) Capital Increase - January 22nd, 2021
Ulcerative Colitis Phase II Study of GSK2831781 Discontinued - January 22nd, 2021
Kiadis announces multiple abstracts related to its K-NK-cell therapy platform have been accepted for presentation at TCT, the Combined Transplantation... - January 22nd, 2021
Immutep Quarterly Activities Report - January 22nd, 2021
ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in... - January 22nd, 2021
Nicox Analyst Coverage Initiated by Edison Investment Research - January 22nd, 2021
PCI Biotech to present at RNA Therapeutics Virtual Conference - January 22nd, 2021
BioCryst Announces Approval of ORLADEYO™ (berotralstat) in Japan for the Prophylactic Treatment of Hereditary Angioedema - January 22nd, 2021
Mydecine Innovations Group Included in First-Ever Psychedelics ETF - January 22nd, 2021
aTyr Pharma to Present Poster Highlighting Research Approach for Identifying Receptor Targets for Extracellular tRNA Synthetases - January 22nd, 2021
Equillium Announces Acceptance of Late-Breaking Abstract for Oral Presentation of Interim Data from EQUATE Study in acute GVHD at the 2021 TCT... - January 22nd, 2021
Ten Leading BioPharma Companies Announce Formation of Accumulus Synergy to Develop Global Data Sharing Platform - January 22nd, 2021
Report from the Extraordinary General Meeting of Immunicum AB (publ) on 22 January 2021 - January 22nd, 2021
Albireo Recognizes International Alagille Syndrome Awareness Day 2021 - January 22nd, 2021
Teligent Regains Compliance with Nasdaq Filing Requirements and Nasdaq Minimum Market Value Rule - January 22nd, 2021
Cambium Networks Corporation Announces Fourth Quarter and Full Year 2020 Reporting Date - January 22nd, 2021
Bioasis Announces Stock Option Grant - January 22nd, 2021
Revive Therapeutics Included in First Psychedelic Exchange Traded Fund - January 22nd, 2021
Better Choice Company Announces Strategic Investment of $2.7 Million, Co-Lead by Insiders and Management - January 19th, 2021
TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China for Priority Review - January 19th, 2021
Yield10 Bioscience Announces Achievement of Proof-of-Concept Milestone for Producing PHA Bioplastic in Field Grown Camelina Plants - January 19th, 2021
XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy - January 19th, 2021
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial - January 19th, 2021
Vallon Pharmaceuticals Announces Presentation of ADAIR Pharmacokinetics and Pharmacodynamic Data at the Virtual 2021 APSARD Annual Meeting - January 19th, 2021
Tarsus Pharmaceuticals, Inc. Appoints Bryan Wahl, MD, JD as General Counsel - January 19th, 2021
Emerald Bioscience Launches Rebrand Including Name Change to Skye Bioscience - January 19th, 2021
NexImmune Appoints Healthcare Innovator Grant Verstandig as New Board Member - January 19th, 2021
Novan Provides Enrollment Update and Announces New Corporate Headquarters - January 19th, 2021
Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences - January 19th, 2021
Neuropathix, Inc. Announces Publication of Its Global PCT Patent for NPTX-204, a Novel Hops-Inspired Neuroprotectant - January 19th, 2021
Bespoke Extracts Increases Conversion Price of Outstanding Discount Convertible Debentures - January 19th, 2021
Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’s Lead Compound LB-100 to Treat Small Cell Lung Cancer - January 19th, 2021
Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes - January 19th, 2021
Tauriga Sciences Inc. to Construct Product Showroom Within its New Corporate Headquarters - January 19th, 2021
Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option - January 19th, 2021
VIRBAC:2020 annual revenue shows strong growth of +5.7% at constant exchange rates and scope (+3.2% at constant rates) - January 19th, 2021
Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference - January 19th, 2021
Agenus to Participate in B. Riley Securities' Oncology Investor Conference - January 19th, 2021
IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant - January 12th, 2021
T2 Biosystems T2SARS-CoV-2™ Panel Proves Effective Amid Global Rise in Variants of the SARS-CoV-2 Virus - January 12th, 2021
Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units - January 12th, 2021
Qilian International Holding Group Limited Announces Pricing of Initial Public Offering - January 12th, 2021
Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health - January 12th, 2021
Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common... - January 12th, 2021
Addex to Present at the Baader Helvea Swiss Equities Conference - January 12th, 2021
iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19 - January 12th, 2021
Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study - January 12th, 2021
BetterLife Provides Shareholder Update and 2021 Product Development Roadmap - January 12th, 2021

Global News Feed commento

Comments Off | data

November 26th, 2020

About... Dr. Matthew Watson

This author published 3474 posts in this site.

Comments are closed.

Previous post - Next post

BioSyent Releases Financial Results for Third Quarter and First Nine Months of 2020

By Dr. Matthew Watson

About... Dr. Matthew Watson

Share

Comments are closed.

Categories

Archives

Recommended Sites